Cidara Therapeutics — 19th Annual Needham Virtual Healthcare Conference 2020
38 slides from Cidara Therapeutics's conference presentation, Apr 14, 2020

Slide 1: New Hope for Serious Infections
New Hope for Serious Infections 19th Annual Needham Virtual Healthcare Conference Corporate Presentation April 14, 2020 © Cidara Therapeutics 2020

Slide 2: Forward-Looking Statements
Forward-Looking Statements clinical development or whether we will be able to These slides contain or whether it will transform the care of BMT patients; access BARDA funding; and whether our Cloudbreak whether the top line results of the STRIVE Part B clinical platform can be expanded to identify p

Slide 3: Cidara investment thesis
SB 12 Cidara investment thesis Leading science on antifungal and antiviral prevention and treatment Rezafungin 1st antifungal in 13 years for 1st line treatment and prophylaxis Treatment – Phase 3 Transform treatment of candidemia and invasive candidiasis Prophylaxis – Phase 3 Transform prevention i

Slide 4: Cidara's pipeline targets fungal and viral infections
Cidara’s pipeline targets fungal and viral infections IND- Program Proposed Indication Discov. in vitro in vivo enable Ph 1 Ph 2 Ph 3 ANTIFUNGAL Treatment of Rezafungin Candidemia & Invasive Candidiasis Prophylaxis of IFD in Rezafungin Blood & Marrow Transplant Patients ANTIVIRAL: CLOUDBREAK PLATFOR

Slide 5: Cidara's pipeline targets multiple unmet medical needs
Cidara’s pipeline targets multiple unmet medical needs Rezafungin Cloudbreak 5

Slide 6: Rezafungin: A novel echinocandin in Phase 3
Rezafungin: A novel echinocandin in Phase 3 Structural modification is designed to yield improved chemical & biological properties • Designed for prolonged PK once weekly dosing in clinical studies • Designed for high exposures potential for improved efficacy • Observed absence of toxic degradation

Slide 7: Status of rezafungin phase 3 development plan
Status of rezafungin phase 3 development plan Phase 3 Treatment Trial Phase 3 Prophylaxis Trial • Monitoring: We are monitoring a • Preparation: We are continuing number of factors affecting our regulatory and clinical activities enrollment and clinical trial to begin initiating sites and operations

Slide 8: Rezafungin overall phase 3 development plan
Rezafungin overall phase 3 development plan 1 Phase 3 Treatment Trial Phase 3 Prophylaxis Trial Treatment of candidemia & Prophylaxis against Aspergillus, Indication invasive candidiasis in patients Candida & PCP in allogeneic blood with limited treatment options and marrow transplant patients Phase

Slide 9: STRIVE B Phase 2 data in candidemia & invasive candidiasis
STRIVE B Phase 2 data in candidemia & invasive candidiasis Corroborates STRIVE A results and supports ReSTORE Phase 3 9

Slide 10: Rezafungin: Superior on time to negative blood culture
Rezafungin: Superior on time to negative blood culture Time to negative blood culture (mITT population) Rezafungin IV 400/200 100% 80% Caspofungin IV 60% Log-rank test: RZF vs CSP 40% p=0.02 20% Probability of of Probability negativecultureblood 0% 0 40 80 120 160 200 Hours since first dose Data on

Slide 11: 30-Day All Cause Mortality – Post Hoc Analysis
30-Day All Cause Mortality – Post Hoc Analysis* STRIVE Program: Rezafungin vs. Caspofungin FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE Phase 3 trial endpoint requires upper -8.8% limit of confidence -24.7% Rezafungin 400/200 +0.41% interval be below 20% threshold 95% confidence interval for FDA 20%

Slide 12: Day 14 Clinical Response – Post Hoc Analysis
Day 14 Clinical Response – Post Hoc Analysis* STRIVE Program: Rezafungin vs. Caspofungin FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE Phase 3 trial endpoint requires upper 9.9% limit of confidence 26.6% Rezafungin 400/200 -6.9% interval be below 20% threshold 95% confidence interval for EMA -20% Non

Slide 13: ReSTORE trial design mirrors STRIVE
ReSTORE trial design mirrors STRIVE All-Cause Mortality (1 ENDPOINT – FDA) Global Global Response Global Response & Global Global Global Response Global Global RResponseesponse ((11° EENDPOINTNDPOINT – EEMA)MA) All cause mortality RResponseesponse Response(1° ENDPOINT – FDA) Rezafungin Dose Option

Slide 14: Our partner for Rezafungin ex-US/Japan
Our partner for Rezafungin ex-US/Japan 120 60 Over €2 50% MARKETS YEARS BILLION Over 50% revenue Active in Over 60 years of asset- European sales derived from new more than 30 led innovation exceeding €1 billion products launched in in Europe Over €2B ex-US the last five years in Europe 14

Slide 15: Rezafungin collaboration recognizes commercial potential
Rezafungin collaboration recognizes commercial potential Data Available at Signing Rights Deal ($ million) ANTIFUNGAL P2 P3 NDA Marketed Cidara / Mundipharma: Rezafungin Ex-US; ex-Japan 568 Basilea / Pfizer: Ex-US; ex-Japan 725 ANTIBIOTICS 0 200 400 600 P2 P3 NDA Marketed Melinta / Menarini: Delaflo

Slide 16: Rezafungin overall phase 3 development plan
Rezafungin overall phase 3 development plan 1 Phase 3 Treatment Trial Phase 3 Prophylaxis Trial Treatment of candidemia & Prophylaxis against Aspergillus, Indication invasive candidiasis in patients Candida & PCP in allogeneic blood with limited treatment options and marrow transplant patients Phase

Slide 17: The current standard of care is inadequate
The current standard of care is inadequate BMT patients discontinue prophylaxis due to adverse events and low tolerability 1 High Posaconazole 34% 1 discontinuation rate Fluconazole 38% 2 Bactrim 35% 90-day mortality in patients with invasive fungal infection3 High Blood and marrow transplant 63% mo

Slide 18: Rezafungin: potential simplified single drug paradigm
Rezafungin: potential simplified single drug paradigm Antifungal prophylaxis in allogeneic blood and marrow transplant setting Fluconazole SOC for Current Fluconazole Posaconazole or Voriconazole Candida and Antifungal Aspergillus Prophylaxis or… Posaconazole or Voriconazole Regimens Bactrim, dapson

Slide 19: ReSPECT Phase 3 prophylaxis trial design
ReSPECT Phase 3 prophylaxis trial design Rezafungin Arm (n=~300) 1 Endpoint: Fungal Free Survival at Day 90 Follow up Week 1 2 3 4 5 12 13 17 Rezafungin Azole placebo Bactrim placebo Day 1 90 120 Comparator Arm (n=~150) Week 1 2 3 4 5 12 13 17 Rezafungin Placebo Azole* *Fluconazole to start in all

Slide 20: COVID-19 patients at risk for fungal infections
COVID-19 patients at risk for fungal infections Working with KOLs to develop clinical protocol Challenge • COVID-19 patients at risk for secondary fungal infections • Similar to fungal infections seen in hospitalized flu patients Risk factors • Use of ventilator / intubation include: • Immunosuppres

Slide 21: Cidara's pipeline targets multiple unmet medical needs
Cidara’s pipeline targets multiple unmet medical needs Rezafungin Cloudbreak 21

Slide 22: Vision for Antiviral Conjugates for respiratory disease
Vision for Antiviral Conjugates for respiratory disease: Single-dose treatment and long-acting protection Against all strains… In all people… 22

Slide 23: Cloudbreak platform – multimodal mechanism of action
SB 10 Cloudbreak platform – multimodal mechanism of action Intrinsic antiviral activity & immune engagement Immune Pathogen Component TARGETING MOIETY (TM) Fc MOIETY • Inhibits essential surface target • Engages immune system • Direct viricidal activity • Extends PK 23

Slide 24: Coronavirus AVCs are being designed to target viral fusion
Coronavirus AVCs are being designed to target viral fusion Untreated Treated 24

Slide 25: Coronavirus - Novel Cloudbreak approaches to treat & prevent
Coronavirus - Novel Cloudbreak approaches to treat & prevent Inhibitor peptides Fc • Novel Fc - peptide fusion AVC inhibitors for SARS and COVID-19 • Goal: fast-acting treatment and long-acting prevention • 16 variants have been generated for first round of testing • Several designs under evaluation

Slide 26: Potential Advantages of AVCs in COVID-19
Potential Advantages of AVCs1 in COVID-19 Utility for rapid treatment and long-term prevention of respiratory diseases • Rapid onset of action • Superior distribution to lung • Months of protection from single dose • Activity in immune compromised hosts 1. The above have been observed in testing of

Slide 27: CD377 for influenza: Validation of the approach in respiratory viruses
SB 12 CD377 for influenza: Validation of the approach in respiratory viruses Broad spectrum, universal coverage Superior resistance profile Protection for High-Risk Populations Expanded efficacy window Long duration of action Rapid onset of activity Flexible administration 27

Slide 28: CD377: a multivalent conjugate of a neuraminidase inhibitor with human Fc domain
SB 9 CD377: a multivalent conjugate of a neuraminidase inhibitor with human Fc domain AVC Direct inhibition of viral TM proliferation – NA inhibition Fc Virion HA NA Additional mechanisms – Additional mechanisms – Immune mediated clearance Improved antiviral activity vs small molecules NK/CD8+ cell

Slide 29: Flu vaccines have well known limitations
SB 11 Flu vaccines have well known limitations… Viral coverage Patient Manufacturing Strain-specific, Less effective in elderly & Challenging in a pandemic: variable coverage immune compromised long, complex production 10%-60% effective ~2-week lag time to Difficult to scale, low yields (2004-2018)1

Slide 30: Flu places a substantial burden on the US population
… which place a substantial burden on the US population 49% 40% or less 9M to 45M immunization rate vaccine effectiveness people who get the flu 31.4M 140K – 810K 12K – 80K outpatient visits hospitalizations deaths The top range of these burden estimates are from the 2017-2018 flu season Sources: CD

Slide 31: ~320M people should be vaccinated/year in US
~320M~320M peoplepeople shouldshould bebe vaccinated/yearvaccinated/year inin USUS OtherOther coco-morbiditiesmorbidities3 100100 1 1 4 ) 8080 FluFlu VaccineVaccine NonNon-believerbeliever M ( n o i t 6060 ElderlyElderly ageage 65+65+ a l u 2 p RespiratoryRespiratory coco-morbiditiesmorbidities o P

Slide 32: CD377 development candidate profile
CD377 development candidate profile Now in IND enabling studies Target Attribute CD377 Indication Universal prevention and treatment All data are supportive Spectrum A & B + drug resistant strains, low Potent in-vivo activity against resistance potential all seasonal and pandemic strains Safety/Tole

Slide 33: AVC Clinical Development Plan (Phase 1a)
AVC Clinical Development Plan (Phase 1a) Phase 1 Safety data to enable BARDA consideration . Phase 1a- SAD/MAD (~1-year duration) . 3 dose groups (10:3 ratio of CD377 : Placebo) low, medium & high dose . Total follow-up of ~4 months following last dose Screened Subjects N=52 Low Dose Subjects Mid Do

Slide 34: Influenza Development Program: Treatment
Influenza Development Program Two Indications- Treatment and Prevention Treatment • Potential advantages based on nonclinical data over current standard of care • Efficacy against all tested strains of Influenza A and B (including H1N1, H3N1, H5N1, H7N9, etc) • Efficacy against oseltamivir- and balo

Slide 35: Influenza Development Program: Prevention
Influenza Development Program Two Indications- Treatment and Prevention Prevention • Potential advantages based on nonclinical data over vaccines • Superiority in high-risk patients with low vaccine efficacy: elderly, cardiac/pulmonary patients, and diabetics, transplant, and other immunosuppressed

Slide 36: Financial overview
Financial overview Summary Consolidated As of December 31, 2019 Balance Sheet Information As Reported Pro Forma Comment 1 PF includes rights offering Cash and restricted cash $60.3M $89.4M proceeds of $29.1M 2 PF includes Series X pref. Common stock issued 40.5M 51.5M shares ‘as converted’ Pacific W

Slide 37: Cidara is much more than a typical ID company
SB 12 Cidara is much more than a typical ID company Strategic Focus Transformative approaches to infectious disease Rezafungin Treatment Enable fast clearance of infection and early discharge vs SOC Rezafungin Prophylaxis Transform the care of BMT patients Cloudbreak AVC Radically different approach

Slide 38: New Hope for Serious Infections
New Hope for Serious Infections 19th Annual Needham Virtual Healthcare Conference Corporate Presentation April 14, 2020 © Cidara Therapeutics 2020
Source: SEC EDGAR · 8-K filed Apr 14, 2020
More decks from Cidara Therapeutics Inc
Corporate Update (June 2025)12 slides · Jun 23, 2025
Investor Presentation (May 2024)63 slides · May 3, 2024
Investor Day (September 2023)58 slides · Sep 21, 2023
Investor Day (July 2022)57 slides · Jul 7, 2022
Technical Presentation (December 2021)24 slides · Dec 14, 2021
Investor Day (September 2021)110 slides · Sep 21, 2021